X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This two-year grant will allow AmideBio to select a long-acting soluble stable glucagon candidate and do the necessary work to support the filing of an Investigational New Drug (IND) application with the FDA at the end of the grant period.
Lead Product(s): Glucagon
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: NIDDK
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Funding October 04, 2022
Details:
US Food and Drug Administration Offices of Pediatric Therapeutics and Orphan Products Development granted a rare pediatric disease designation to AmideBio’s glucagon analog (AB‐G023) for the treatment of congenital hyperinsulinism (CHI).
Lead Product(s): AB-G023
Therapeutic Area: Genetic Disease Product Name: AB-G023
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2020
Details:
AB-G023 is a solution stable, soluble glucagon analog designed to overcome the limitations of glucagon. Glucagon is an effective treatment for congenital hyperinsulinism, but rendered impractical for long term administration given its instability in solution.
Lead Product(s): AB-G023
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
